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Summary
Asthma and COPD are the most frequent chronic respiratory diseases. Although they have different characteristics,
some individuals share features of both diseases, which has been called the asthma-COPD overlap syndrome
(ACOS). Although there is not a universally accepted definition for ACOS, it was initially defined as symptoms
of increased variability of airflow in association with an incompletely reversible airflow obstruction. The most
recent COPD guidelines include this phenotype and its diagnostic features.
Patients with ACOS are usually characterized by increased reversibility of airflow obstruction, eosinophilic bronchial
and systemic inflammation, and increased response to inhaled corticosteroids, compared with COPD patients.
The relevance of the ACOS is the need to identify patients with COPD who may have underlying eosinophilic
inflammation that responds better to inhaled corticosteroids. Until new diagnostic tools are developed, a previous
diagnosis of asthma in a patient with COPD can be a reliable criterion to suspect ACOS in a patient with
COPD but a comprehensive approach may be required in most cases for a definitive diagnosis of ACOS.
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Introduction
Chronic obstructive pulmonary disease (COPD) is an
underdiagnosed disease with a high morbidity and mor-
tality and is a very significant public health problem. In
Europe the estimated prevalence varies from 2.1 % and
26.1 % between countries [1]. Given its high prevalence,
COPD entails a high burden in all the levels of care.
In recent years, there has been a growing interest in
defining and characterising COPD patients into different
phenotypes that share clinical features, similar response
to the available treatments and that may have prognostic
implications [2, 3]. Among these, the asthma-COPD
overlap syndrome (ACOS) is a clear example that fulfils
all the criteria and is currently kindling great interest.
COPD and asthma have clear differences, but some pa-
tients may present with a mixture of both diseases. ACOS
may be a manifestation of characteristics of the asthma
and COPD that the patient is suffering from. Clinically,
the ACOS usually corresponds to asthmatic smokers who
develop non-fully reversible airway obstruction, however,
when the previous history of asthma is unknown, the diag-
nosis of ACOS may be difficult due to the lack of specific
biomarkers. In many cases the correct diagnosis of ACOS
will require a comprehensive approach including clinical
manifestations, spirometry with bronchodilator test, iden-
tification of eosinophilic inflammation, lung volumes and
carbon monoxide diffusion capacity and even CT scan,
and such diagnosis should be made by a specialist [4].
The interest in recognizing these individuals lies in
their better response to inhaled corticosteroids (ICS)
compared to those with COPD. This specific and differ-
ential treatment justifies the efforts to differentiate the
subgroup of patients with ACOS from the large popula-
tion of COPD patients.
Definition and clinical features
From a COPD perspective, the identification of ACOS is
relevant to describe a subgroup of smokers with COPD
that share some pathogenic and inflammatory character-
istics with asthma. Patients with ACOS are also more
likely to be frequent exacerbators (defined as the pres-
ence of 2 or more exacerbations per year), to have re-
duced physical activity, worse quality of life and more
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respiratory symptoms, particularly dyspnoea and wheez-
ing, than patients with COPD alone [5, 6].
ACOS has been defined as symptoms of increased
variability of airflow in association with incompletely re-
versible airflow obstruction [7]. More recently, Louie et
al. [8] defined ACOS as asthma with partially reversible
airflow obstruction, with or without emphysema or re-
duced carbon monoxide diffusing capacity (DLCO) to
<80 % predicted, and COPD with emphysema accom-
panied by reversible or partially reversible airflow ob-
struction, with or without environmental allergies or
reduced DLCO. Izquierdo-Alonso et al. [9] identified
ACOS as patients with COPD (more than 10 pack-years
of smoking and post-bronchodilator FEV1/FVC < 0.7)
and a personal history of asthma before the age of 40,
with the addition of normal carbon monoxide (CO) dif-
fusing capacity and the absence of pulmonary emphy-
sema demonstrated by imaging techniques.
It is important to recognise that the presence of chronic
non-fully reversible airflow obstruction in a subject with
asthma is not necessarily ACOS. It is well known that se-
vere asthma patients may develop non-reversible airflow
limitation without any characteristics of COPD [10].
The definition of ACOS is also included in some of
the latest guidelines. The Spanish guidelines of COPD
identify ACOS patients based on some diagnostic cri-
teria: A) Major criteria: very positive bronchodilator re-
sponse (>400 ml and >15 % in FEV1), sputum
eosinophilia or previous diagnosis of asthma. B) Minor
criteria: increased total serum IgE, previous history of
atopy or positive bronchodilator test (>200 mL and >12 %
in FEV1) on at least two occasions [11, 12]. To be diag-
nosed with ACOS, a patient must fulfil two major or one
major and two minor criteria. The recent Czech Republic
and Finnish guidelines also include ACOS with its own
diagnostic criteria. In the Czech Republic diagnostic
guidelines major criteria include a strong bronchodilator
test positivity (FEV1 > 15 % and > 400 ml), positive
bronchial challenge test, FeNO > 45–50 ppb and/or
sputum eosinophilia ≥3 % and a previous histoy of
asthma, and as minor criteria: mild bronchodilator
test positivity (FEV1 > 12 % and > 200 ml), increased
total IgE and history of atopy [13]. The main Finnish diag-
nostic criteria are also a significant bronchodilatory effect
(FEV1 > 15 % and > 400 ml), sputum eosinophilia or ele-
vated ENO (>50 ppb) and previous asthma symptoms
(starting before the age of 40). As additional criteria they
include an elevated total IgE, atopy, repeated significant
bronchodilatory response (FEV1 > 12 % and >200 ml) and
a PEF-follow up typical of asthma [14]. For both guide-
lines, a patient must fulfil two major (or main) criteria or
one major and two minor (or additional) criteria.
A recent GOLD-GINA document about ACOS de-
scribes this syndrome as persistent airflow limitation
with several features usually associated with asthma and
several features usually associated with COPD [15].
Diagnosis: current and future strategies
In asthma the term endotype has been introduced to
identify subtypes of patients defined by a distinct func-
tional of pathophysiological mechanism [16]. It is pos-
sible that different mechanisms in patients suffering
from asthma or COPD could lead to the clinical expres-
sion that we now define as ACOS. Most studies define
ACOS as a phenotype of COPD. There is no unified def-
inition of ACOS but some main features can help us to
identify this phenotype. In patients with COPD, in-
creased reversibility is one of the key differential aspects
of individuals with ACOS, but it can be misleading if
taken alone. Significant reversibility in COPD is com-
mon and observed frequently in clinical practice and in
series of patients included in clinical trials [17]. Some-
what more than 50 % of the patients with moderate-to-
very-severe COPD in the UPLIFT clinical trial met the
most commonly used criteria for acute bronchodilator
responsiveness [18]. Related to this bronchodilator re-
sponse, bronchial hyperresponsiveness (BHR) is ob-
served in almost all patients with asthma, especially in
those with active symptoms and in up to two-thirds of
COPD patients [19]. Furthermore, BHR is observed in
aproximately 10 % to 20 % of the general population and
has shown to be a risk factor of developing asthma and
COPD [8]. In patients with established asthma or COPD,
more severe BHR is associated with more severe symp-
toms and a more rapid decline in FEV1 [20]. Nevertheless,
in a population of COPD patients without significant co-
morbidities, individuals with high levels of reversibility
presented better long-term outcomes [21]. These contro-
versial results underscore the need of a specialised ap-
proach to the diagnosis and assessment of the patients
with ACOS.
Possibly the most important diagnostic feature of ACOS
in COPD is the presence of sputum eosinophilia. Inflam-
mation in asthma patients is considered to be mainly
eosinophilic and mediated by CD4+ T lymphocytes while
in COPD it is neutrophillic and driven by CD8+. Papi et
al. [22] observed that peripheral eosinophilic counts and
sputum eosinophil counts were significantly higher in
stable COPD patients with partial reversibility of airflow
limitation compared to COPD patients without reversibil-
ity. Since sputum eosinophilia is not routinely performed
in clinical practice, indirect markers of this type of inflam-
mation have been investigated. Chou et al. [23] demon-
strated higher levels of exhaled nitric oxide (eNO) in
patients with COPD and eosinophilic airway inflammation
(>3 % eosinophils in induced sputum), with a cut off of
23.5 ppb of eNO having a sensitivity of 62.1 % and a speci-
ficity of 70.5 % for the identification of eosinophilic
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inflammation. Interestingly, patients with COPD and
peripheral eosinophilic inflammation treated with ICS
present fewer exacerbations compared to those with
lower blood count levels [24].
Other plasma and sputum biomarkers of ACOS are
currently being studied. Iwamoto et al. [25] investigated
four potential biomarkers in COPD (surfactant protein
A (SP-A), soluble receptor for advanced glycation end
products (sRAGE), myeloperoxidades (MPO) and neu-
trophil gelatinase associated lipocalin (NGAL)). Com-
pared with asthma patients, sputum MPO and plasma
SP-A were significantly elevated in ACOS, while only
sputum NGAL was significantly increased compared to
COPD. Fu et al. [26] examined the levels of the systemic
inflammation markers PCR and IL-6 in asthma, COPD
and ACOS patients and identified potential clinical char-
acteristics that were associated with these biomarkers.
They found a high prevalence of systemic inflammation
in older people with ACOS and an elevated IL-6 com-
pared with asthma patients. Age, Charlson comorbidity
index and IL-6 were independently associated with
ACOS while IL-6 was independently associated with air-
flow obstruction and cardiovascular disease suggesting
that it may be involved in these two processes and may
therefore be an independent treatment target [26].
There is a growing interest in the identification of gen-
etic determinants for ACOS. Genetic analysis of the
COPD gene cohort identified several variants associated
with ACOS, which may demonstrate distinct genetic risk
factors [27]. Christenson et al. [28] investigated whether
asthma-associated gene signatures were increased in a
subgroup of COPD patients and associated with asthma-
related features, consisting in eosinophilia and type 2
(TH2) inflammation. In their study, the investigators
developed a 100 gene signature of the Th2-related gene
expression, the T2S score that correlated well with Th2-
associated clinical characteristics in asthmatic patients
and found that approximately 20 % of their COPD pa-
tients had increased expression of T2S. They next inves-
tigated the association of T2S with clinical parameters in
the GLUCOLD cohort of patients with COPD. T2S was
significantly associated with increased tissue eosinophil
numbers, increased serum eosinophil percentage and in-
creased bronchodilator responsiveness (Fig. 1). Interest-
ingly, a higher T2S was associated with greater reduction
in hyperinflation after ICS (with or without LABA) treat-
ment versus placebo at 30 months [28]. Nevertheless, al-
beit promising, these techniques are not available in every
centre and cannot yet be used as a diagnostic tool in clin-
ical practice.
Epidemiology of ACOS
Data derived from large population studies have re-
vealed that a high proportion of adult patients with
respiratory symptoms are commonly diagnosed with
more than one obstructive lung disease, especially
elderly individuals [29].
More interesting is the prevalence of ACOS observed
among populations of patients diagnosed with COPD.
This prevalence can be estimated from research data-
bases or clinical studies. The prevalence of ACOS de-
rived from clinical studies is usually lower compared
with the analysis of databases, due to the use of more re-
strictive diagnostic criteria. Using the criteria established
by the Spanish National Consensus Conference (Table 1),
in a cross sectional study with 279 COPD patients Mira-
vitlles et al. [30] observed a prevalence of ACOS of 5 %.
A larger survey in 3125 COPD patients using the same
Fig 1 Clinical expression of the asthma-COPD overlap syndrome (ACOS). The ACOS usually corresponds to a smoker asthmatic patient that
develops non fully reversible airway obstruction and/or a COPD individual (with or without a known history of asthma) with a Th2 signature (increased
blood and lung eosinophilia, increased airway hyper-responsiveness, and better response to ICS). Reproduced with permission from ref. [43]
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criteria observed a prevalence of ACOS of 3.9 %. How-
ever, this prevalence increased to 15.9 % when using the
criterion of a previous diagnosis of asthma [31]. In a
retrospective observational study of 499 patients with
COPD Golpe et al. [32] observed a similar prevalence
(5 %) in smoking-related COPD patients but with a
higher frequency of ACOS in COPD patients caused by
inhalation of biomass smoke (21.2 %). Following modi-
fied criteria from the Spanish consensus that included a
normal diffusion capacity for carbon monoxide (DLCO),
Izquierdo-Alonso et al. [9] detected a prevalence of
ACOS of 12 % in an observational, multicentre study
Table 1 Asthma-COPD overlap syndrome, definitions and diagnostic criteria
Gibson P, Simpson J [7], 2009 Asthma and COPD (symptoms of increased variability of airflow and incompletely reversible
airflow obstruction)
COPD gene [5],2011 Patients with COPD and a diagnosis of asthma before the age of 40
Spanish consensus [11], 2012 (patients must fulfill
2 major criteria or 1 major and 2 minor)
Major criteria
Very positive bronchodilator response (>400 ml and >15 % in FEV1)
Sputum eosinophilia
Previous diagnosis of asthma
Minor criteria
Increased total serum IgE
Previous history of atopy
Positive bronchodilator test (>200 mL and >12 % in FEV1) on at least two occasions
Czech Republic guidelines [13], 2013 (patients must
fulfill 2 major criteria or 1 major and 2 minor)
Major criteria
Strong bronchodilator test positivity (FEV1 > 15 % and > 400 ml)
Positive bronchial challenge test
FeNO > 45–50 ppb and/or sputum eosinophilia ≥3 %
Histoy of asthma
Minor criteria
Mild bronchodilator test positivity (FEV1 > 12 % and > 200 ml)
Increased total IgE
History of atopy
Louie S et al. [8], 2013 -Asthma with partially reversible airflow obstruction with/without emphysema or reduction of
DLCO <80 % predicted.
-COPD with emphysema accompanied by reversible or partially reversible airflow obstruction,
with or without environmental allergies or reduced DLCO
Menezes M et al. [30], 2013 FEV1/FVC <0.7 and medical diagnosis of asthma or wheezing + positive bronchodilator test
(>200 mL and >12 % in FEV1)
Izquierdo-Alonso et al. [9] (2013) COPD (more than 10 pack-years and post bronchodilator FEV1/FVC < 0.7)
History of asthma before the age of 40
Normal carbon monoxide (CO) diffusion capacity and absence of pulmonary emphysema
demonstrated by imaging techniques
GOLD-GINA document [15] (2014) Persistent airflow limitation with several features usually associated with asthma and several
features usually associated with COPD
Finish guidelines [14] (2014) (patients must
fulfill 2 main criteria or 1 main and 2 additional)
Main criteria
Significant bronchodilatory effect (FEV1 > 15 % and > 400 ml)
Sputum eosinophilia or elevated ENO (>50 ppb)




Repeated significant bronchodilatory response (FEV1 > 12 % and >200 ml)
PEF-follow up typical of asthma
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performed in 331 COPD patients recruited in pulmonol-
ogy outpatient services. Similar frequencies have been de-
scribed in studies performed in other countries [5, 8]. In
the COPD Gene study, Hardin and colleges found that
13 % of subjects with COPD also reported physician-
diagnosed asthma [5]. In epidemiological studies such as
the PLATINO study performed in Latin America, a preva-
lence of 11.6 % was described using a postbronchodilator
FEV1/FVC < 0.7 and asthma diagnosis as ACOS criteria
[33]. In the Spanish EPISCAN epidemiological study, in-
cluding patients with COPD and previous diagnosis of
asthma before the age of 40, a prevalence of 17.4 % of
ACOS was observed among the COPD population [34].
Treatment
There is little information about the response of ACOS
patients to most of the current pharmacological therap-
ies as they have been systematically excluded from both
COPD and asthma pharmacological trials. The only clin-
ical trial performed to date in patients with ACOS stud-
ied the effects of tiotropium in 472 individuals with
concomitant COPD and asthma. Improvements in lung
function and a reduction in rescue medication were ob-
served with tiotropium [35]. However, the main interest
in differentiating ACOS from COPD lies in the different
response to ICS. Some studies demonstrate that patients
with COPD and eosinophilic inflammation treated with
ICS present a significant improvement in bronchial in-
flammation together with clinical and spirometric im-
provement [36, 37]. Two small, randomised trials have
demonstrated that prescribing corticosteroids (oral or
inhaled) according to the intensity of bronchial eosino-
philic inflammation in patients with COPD was signifi-
cantly superior in preventing exacerbations and improving
health-related quality of life compared with the prescrip-
tion of ICS according to current guidelines [38, 39].
Already in 2007 the Canadian guidelines specified that:
“if the asthma component (in COPD) is prominent, earl-
ier introduction of ICS may be justified” [40]. Later, in
2010, the Japanese guidelines of COPD dedicated a
chapter to “Treatment of COPD complicated by asthma”
[41] and indicate that ICS combined with long-acting
beta-2 agonists (LABA) would be the first choice treat-
ment irrespective of the level of airflow obstruction.
More recently, the Spanish guidelines of COPD, the
Czech Republic guidelines and the Finnish guidelines ad-
dress the indication of ICS in the patients with ACOS in
all stages of severity [13, 14].
New treatments targeting a reduction in eosinophilic
concentrations are being developed. Among them, the
anti-IL5 benralizumab has not proven to reduce exacer-
bations in COPD patients with peripheral eosinophilia,
but patients with the highest eosinophilic count showed
improvements in FEV1 and a reduction in the exacerba-
tions rate, which support further investigation [42].
Conclusion
Patients with ACOS show 3 characteristic features that
help us to identify them: enhanced bronchial and sys-
temic eosinophilic inflammation, increased reversibility
of airflow and increased response to ICS compared with
patients with COPD alone. Whether one believes in the
existence of ACOS or just in the coexistence of these
two different diseases in the same individual, it is clear
that patients with ACOS are different from those with
asthma and COPD. Although these patients share fea-
tures with both asthma and COPD, they have some dif-
ferent clinical characteristics and prognosis and what it
more important, a better response to ICS.
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